Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats

Journal of Pharmacological Sciences

Volumn 125, Issue 4, 2014, Pages 386-393

  Takai, Shinji ^a   Sakonjo, Hiroshi ^b   Jin, Denan ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Frontier Technology Department Research and Development Division Shiga Technical Center   (Japan)

Author keywords

Diabetes; Dipeptidyl peptidase 4; Inhibitor; Penetration; Vascular tissue

Indexed keywords

ACETYLCHOLINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; MALONALDEHYDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; P22PHOX PROTEIN; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SITAGLIPTIN; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; P22-PHOX PROTEIN, RAT; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PROTECTION; PROTEIN BLOOD LEVEL; RAT; VASCULAR PROTECTION; VASCULAR RELAXATION; ZUCKER RAT; ANIMAL; ATHEROSCLEROSIS; BLOOD; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; BLOOD GLUCOSE; CAROTID ARTERIES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; IN VITRO TECHNIQUES; INSULIN; MALONDIALDEHYDE; NADPH OXIDASE; PURINES; PYRAZINES; QUINAZOLINES; RATS, ZUCKER; TRIAZOLES; VASODILATION;

EID: 84906957817     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14052FP     Document Type: Article

References (32)

1. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis. 1998; 137 Suppl: S65-S73.
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26: 881-885.
3. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106: 2067-2072.
4. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295: 1681-1687.
5. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem. 2009; 16: 2943-2951.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004; 287: E199-E206.
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 1696-1705.
8. Lotfy M, Singh J, Kalász H, Tekes K, Adeghate E. Medicinal Chemistry and Applications of Incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J. 2011; 5 Suppl 2: 82-92.
9. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010; 30: 1407-1414.
10. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001; 102: 81-86.
11. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287: E1209-E1215.
12. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51: 501-514.
13. Takai S, Jin D, Yamamoto D, Li ZL, Otsuki Y, Miyazaki M. Significance of matrix metalloproteinase-9 inhibition by imidapril for prevention of abdominal aortic aneurysms in angiotensin II type 1 receptor-knockout mice. J Pharmacol Sci. 2013; 123: 185-194.
14. Kirino Y, Kamimoto T, Sata Y, Kawazoe K, Minakuchi K, Nakahori Y. Increased plasma dipeptidyl peptidase IV (DPP IV) activity and decreased DPP IV activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet. Biol Pharm Bull. 2009; 32: 463-467.
15. Takai S, Jin D, Shimosato T, Sakonjo H, Miyazaki M. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2011; 34: 245-252.
16. Clark JB, Palmer CJ, Shaw WN. The Diabetic Zucker Fatty rat. Proc Soc Exp Biol Med. 1983; 173: 68-75.
17. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, et al. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology. 2013; 154: 2501-2513.
18. Takai S, Jin D, Sakaguchi M, Miyazaki M. Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res. 2004; 27: 213-219.
19. Takai S, Kirimura K, Jin D, Muramatsu M, Yoshikawa K, Mino Y, et al. Significance of angiotensin II receptor blocker lipo-philicities and their protective effect against vascular remodeling. Hypertens Res. 2005; 28: 593-600.
20. Hjøllund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia. 2011; 54: 2206-2208.
21. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and -independent pathways. Circulation. 2008; 117: 2340-2350.
22. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996; 137: 2968-2978.
23. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009; 201: 59-66.
24. Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012; 59: 265-276.
25. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59: 1030-1037.
26. Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides. 2014; 54C: 19-26.
27. Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012; 96: 140-149.
28. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol. 2011; 55: 2-9.
29. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19: 257-267.
30. Christ M, Bauersachs J, Liebetrau C, Heck M, Günther A, Wehling M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes. 2002; 51: 2648-2652.
31. Laudes M, Oberhauser F, Schulte DM, Schilbach K, Freude S, Bilkovski R, et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp Clin Endocrinol Diabetes. 2010; 118: 473-477.
32. Wrenger S, Faust J, Friedrich D, Hoffmann T, Hartig R, Lendeckel U, et al. Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function. J Leukoc Biol. 2006; 80: 621-629.